
    
      Patients with NK/T cell lymphoma usually have a bad prognosis. These patients cannot be
      treated successfully with the conventional chemotherapy of CHOP. The investigators have been
      proceeding this trial to evaluate the efficacy and safety of the combination chemotherapy
      regiment DDGP (gemcitabineï¼Œpegaspargase, cisplatin, dexamethasone) in the patients with stage
      I/II NK/T cell lymphoma.
    
  